CY1121678T1 - Νεο αντισωμα εναντι του ανθρωπινου υποδοχεα tslp - Google Patents
Νεο αντισωμα εναντι του ανθρωπινου υποδοχεα tslpInfo
- Publication number
- CY1121678T1 CY1121678T1 CY20191100496T CY191100496T CY1121678T1 CY 1121678 T1 CY1121678 T1 CY 1121678T1 CY 20191100496 T CY20191100496 T CY 20191100496T CY 191100496 T CY191100496 T CY 191100496T CY 1121678 T1 CY1121678 T1 CY 1121678T1
- Authority
- CY
- Cyprus
- Prior art keywords
- human tslp
- tslp receptor
- antibody against
- seq
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
[Πρόβλημα]Η παροχή ενός αντισώματος έναντι του ανθρώπινου υποδοχέα TSLP που δεσμεύεται ειδικά στον ανθρώπινο υποδοχέα TSLP και αναστέλλει μία δράση της ανθρώπινης TSLP μέσω του ανθρώπινου υποδοχέα TSLP. [Μέσα για Επίλυση] Από τους εφευρέτες της παρούσας μελετήθηκε ένα αντίσωμα έναντι του ανθρώπινου υποδοχέα TSLP και παρασχέθηκε ένα αντίσωμα έναντι του ανθρώπινου υποδοχέα TSLP που περιλαμβάνει μία μεταβλητή περιοχή βαριάς αλύσου που αποτελείται από την αλληλουχία αμινοξέων των αμινοξέων με αριθμούς 1 έως 118 της ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 1 και μία μεταβλητή περιοχή ελαφριάς αλύσου που αποτελείται από την αλληλουχία αμινοξέων των αμινοξέων με αριθμούς 1 έως 108 της ΑΚΟΛ. ΑΡ. ΤΑΥΤ.: 3. Αποκαλύφθηκε ότι το αντίσωμα έναντι του ανθρώπινου υποδοχέα TSLP αναστέλλει την έκφραση του TARC mRNA που επάγεται από την TSLP και την παραγωγή πρωτεϊνών MDC και κατέστειλε μία αλλεργική αντίδραση σε ένα πρότυπο ευαισθητοποιήσεως πιθήκου με αντιγόνο ασκαρίδας και εν συνεχεία η παρούσα εφεύρεση ολοκληρώθηκε.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013165676 | 2013-08-09 | ||
| PCT/JP2014/071008 WO2015020193A1 (ja) | 2013-08-09 | 2014-08-08 | 新規抗ヒトｔｓｌｐ受容体抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121678T1 true CY1121678T1 (el) | 2020-07-31 |
Family
ID=52461517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100496T CY1121678T1 (el) | 2013-08-09 | 2019-05-08 | Νεο αντισωμα εναντι του ανθρωπινου υποδοχεα tslp |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US9328171B2 (el) |
| EP (1) | EP3031913B1 (el) |
| JP (1) | JP6380394B2 (el) |
| KR (1) | KR102260680B1 (el) |
| AR (1) | AR097293A1 (el) |
| AU (1) | AU2014303356B2 (el) |
| BR (1) | BR112016002743B1 (el) |
| CA (1) | CA2920484C (el) |
| CY (1) | CY1121678T1 (el) |
| DK (1) | DK3031913T3 (el) |
| ES (1) | ES2730978T3 (el) |
| HR (1) | HRP20190752T1 (el) |
| HU (1) | HUE043111T2 (el) |
| IL (1) | IL243851B (el) |
| LT (1) | LT3031913T (el) |
| MX (1) | MX369208B (el) |
| MY (1) | MY177098A (el) |
| PH (1) | PH12016500237B1 (el) |
| PL (1) | PL3031913T3 (el) |
| PT (1) | PT3031913T (el) |
| RS (1) | RS58696B1 (el) |
| RU (1) | RU2689528C2 (el) |
| SG (1) | SG11201600935SA (el) |
| SI (1) | SI3031913T1 (el) |
| TR (1) | TR201906969T4 (el) |
| TW (1) | TWI635097B (el) |
| UA (1) | UA119328C2 (el) |
| WO (1) | WO2015020193A1 (el) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202012778YA (en) * | 2015-12-18 | 2021-01-28 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2022010912A1 (en) | 2020-07-06 | 2022-01-13 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CN116528897A (zh) | 2020-08-26 | 2023-08-01 | 旗舰开拓创新六世公司 | 靶向SARS-CoV-2的抗原结合分子 |
| CN114853888B (zh) * | 2021-02-05 | 2023-11-03 | 上海洛启生物医药技术有限公司 | 抗tslp纳米抗体及其应用 |
| CN113069543B (zh) * | 2021-06-07 | 2021-08-06 | 迈威(上海)生物科技股份有限公司 | 包含抗胸腺基质淋巴细胞生成素的单克隆抗体的液体组合物 |
| US20240360233A1 (en) * | 2021-08-27 | 2024-10-31 | Board Of Regents, The University Of Texas System | Anti-tslpr (crlf2) antibodies |
| CN114028562B (zh) * | 2021-11-01 | 2022-05-24 | 江苏荃信生物医药股份有限公司 | 包含抗人胸腺基质淋巴细胞生成素(tslp)单克隆抗体的液体制剂 |
| CN117209603B (zh) * | 2021-12-02 | 2024-02-27 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
| CN116217725B (zh) * | 2021-12-02 | 2023-09-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp单克隆抗体的纯化方法 |
| EP4519310A1 (en) | 2022-05-06 | 2025-03-12 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| TW202432601A (zh) * | 2022-11-07 | 2024-08-16 | 美商上游生物公司 | 包含抗人類ｔｓｌｐ受體抗體之醫藥組成物及其使用方法 |
| AR134102A1 (es) * | 2023-10-12 | 2025-12-03 | Innovent Biologics Suzhou Co Ltd | ANTICUERPOS ANTI-IL-4Ra Y USOS DE LOS MISMOS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| KR100337069B1 (ko) | 1993-03-11 | 2002-10-11 | 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 | 항-hiv모노클로날항체 |
| ES2391124T3 (es) * | 2000-06-28 | 2012-11-21 | Amgen Inc. | Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050249712A1 (en) * | 2004-03-23 | 2005-11-10 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for use of TSLP and agonists and antagonists thereof |
| CA2635599C (en) * | 2006-01-13 | 2014-06-17 | Irm Llc | Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases |
| UA120027C2 (uk) * | 2006-12-14 | 2019-09-25 | Шерінг-Плау Лтд. | Ізольоване антитіло проти собачого тимусного стромального лімфопоетину (tslp) |
| CN102027012A (zh) * | 2007-06-20 | 2011-04-20 | Irm责任有限公司 | 用于治疗变应性疾病的方法和组合物 |
| EP2250199B1 (en) | 2008-02-07 | 2015-09-02 | Merck Sharp & Dohme Corp. | Engineered anti-tslpr antibodies |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| WO2012015696A1 (en) * | 2010-07-26 | 2012-02-02 | Baylor Research Institute | Thymic stromal lymphopoietin (tslp) and ox40 ligand in cancer |
| US9732151B2 (en) * | 2011-11-03 | 2017-08-15 | Merck Sharp & Dohme Corp. | Biomarkers for TSLP treatment |
-
2014
- 2014-08-08 UA UAA201602101A patent/UA119328C2/uk unknown
- 2014-08-08 RU RU2016107814A patent/RU2689528C2/ru active
- 2014-08-08 TR TR2019/06969T patent/TR201906969T4/tr unknown
- 2014-08-08 BR BR112016002743-4A patent/BR112016002743B1/pt active IP Right Grant
- 2014-08-08 AR ARP140102993A patent/AR097293A1/es active IP Right Grant
- 2014-08-08 JP JP2015530978A patent/JP6380394B2/ja active Active
- 2014-08-08 ES ES14833804T patent/ES2730978T3/es active Active
- 2014-08-08 DK DK14833804.9T patent/DK3031913T3/da active
- 2014-08-08 HR HRP20190752TT patent/HRP20190752T1/hr unknown
- 2014-08-08 MX MX2016001796A patent/MX369208B/es active IP Right Grant
- 2014-08-08 CA CA2920484A patent/CA2920484C/en active Active
- 2014-08-08 HU HUE14833804A patent/HUE043111T2/hu unknown
- 2014-08-08 TW TW103127264A patent/TWI635097B/zh active
- 2014-08-08 SG SG11201600935SA patent/SG11201600935SA/en unknown
- 2014-08-08 LT LTEP14833804.9T patent/LT3031913T/lt unknown
- 2014-08-08 KR KR1020167005884A patent/KR102260680B1/ko active Active
- 2014-08-08 EP EP14833804.9A patent/EP3031913B1/en active Active
- 2014-08-08 PL PL14833804T patent/PL3031913T3/pl unknown
- 2014-08-08 PT PT14833804T patent/PT3031913T/pt unknown
- 2014-08-08 SI SI201431208T patent/SI3031913T1/sl unknown
- 2014-08-08 WO PCT/JP2014/071008 patent/WO2015020193A1/ja not_active Ceased
- 2014-08-08 MY MYPI2016700421A patent/MY177098A/en unknown
- 2014-08-08 AU AU2014303356A patent/AU2014303356B2/en active Active
- 2014-08-08 RS RS20190580A patent/RS58696B1/sr unknown
-
2015
- 2015-10-29 US US14/927,007 patent/US9328171B2/en active Active
-
2016
- 2016-01-28 IL IL24385116A patent/IL243851B/en active IP Right Grant
- 2016-02-03 PH PH12016500237A patent/PH12016500237B1/en unknown
- 2016-04-04 US US15/090,051 patent/US9908941B2/en active Active
-
2019
- 2019-05-08 CY CY20191100496T patent/CY1121678T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121678T1 (el) | Νεο αντισωμα εναντι του ανθρωπινου υποδοχεα tslp | |
| CY1124670T1 (el) | Μεθοδοι και συνθεσεις για την παροχη mrna κωδικοποιημενων αντισωματων | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| CY1124095T1 (el) | Μεθοδοι για την ενισχυση της ειδικης ανοσοθεραπειας εναντι αλλεργιογονου με χορηγηση αναστολεα του ιl-4r | |
| CY1119055T1 (el) | Αντισωματα που προσδενονται στην il-17a και στην il-17f | |
| CY1120849T1 (el) | Αντισωμα που συνδεεται σε ανθρωπινο cd3 | |
| CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
| CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
| CY1124698T1 (el) | Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
| CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| MX2021011167A (es) | Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso. | |
| CY1119849T1 (el) | Προ-συντηξης rsv f αντιγονα | |
| CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
| PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
| EA201690333A1 (ru) | МОДУЛОКИНЫ НА ОСНОВЕ ДОМЕНА SUSHI IL-15 И IL-15Rα | |
| CY1125400T1 (el) | Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων | |
| PE20161032A1 (es) | Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion | |
| CY1115030T1 (el) | Διειδικα αντι-vegf/αντι-ang-2 αντισωματα | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
| NZ631098A (en) | Anti-hepcidin antibodies and uses thereof | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 |